ReviewFrontiers in pediatrics2026
Efficacy and safety of bosentan-related therapy in neonates with persistent pulmonary hypertension of the newborn: a systematic review and meta-analysis.
Review in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of bosentan-related therapy in neonates with persistent pulmonary hypertension of the newborn (PPHN). Methods: PubMed, Web of Science, the Cochrane Library, and ClinicalTrials.gov were searched from inception to March 2026 for clinical studies of bosentan in neonates with PPHN (CRD420261338730). Two reviewers independently screened studies, extracted data, and assessed risk of bias. Meta-analysis was performed using RevMan 5.4. Outcomes included treatment failure, change in pulmonary artery pressure, length of hospital stay, duration of mechanical ventilation, absolute tricuspid regurgitation values at 72 h, reduction in tricuspid regurgitation at 72 h, and safety. Results: Nine studies were included from 187 identified records. Bosentan-related therapy was associated with a lower treatment failure rate than control treatment (RR: 0.27, 95% CI: 0.14-0.51; Conclusion: Bosentan-related therapy may be associated with a lower risk of treatment failure and favorable changes in echocardiography-derived pulmonary pressure estimates in neonates with PPHN. However, current evidence does not support a clear benefit in harder clinical outcomes such as length of hospital stay, and no reduction in duration of mechanical ventilation was observed. Short-term safety appears acceptable, but caution remains warranted. Clinical Trial Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420261338730. PROSPERO: CRD420261338730.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.